Shuck Corporation Attends ISA Event on Eli Lilly’s Medicine Foundry Project
On April 29, Shuck Corporation attended the an ISA event hosted at VisionLoft Stutz to learn more about Eli Lilly and Company’s upcoming Medicine Foundry project. This groundbreaking initiative will establish a 200-acre clinical trial manufacturing campus, significantly enhancing Lilly’s capacity to produce innovative therapies, including small molecules, oligonucleotides, peptides, and antibody-drug conjugates (ADCs).
The event brought together industry leaders and potential partners to discuss the scale, impact, and opportunities associated with the project. Representatives from Foundry Partners shared insights into the facility’s future role in accelerating drug development and outlined preliminary bidding details for firms interested in contributing to the project.
Shuck Corporation is proud to engage with projects that drive innovation and economic growth across Indiana’s life sciences and advanced manufacturing sectors.
